N ew drugs and new approaches to prevent and manage HIV infection necessitate an update to the International Antiviral (formerly AIDS) Society-USA (IAS-USA) recommendations, last published in 2016. 1 This report incorporates current data on new regimens and new approaches into recommendations for the treatment and prevention of HIV.
Methods
Recommendations were developed by an international panel of 16 volunteer experts in HIV research and care. Members were screened for expertise, involvement in research and care, financial relationships, and ability to work toward consensus (ie, ability to consider all available data, evidence, and group discussions or opinions to reach agreement on recommendations). The panel convened in person (N =2) and by conference calls (N = 10 full-panel and multiple subgroup calls) from September 2017 to June 2018. Teams for each section evaluated relevant evidence and drafted recommendations for full-panel review.
New evidence used was published in the literature, presented at major conferences, or released as safety reports. 1 Monthly literature searches were conducted in PubMed and EMBASE between July 2016 and April 2018. Approximately 237 relevant citations were identified from more than 4490 reports. Abstracts presented at scientific conferences since July 2016 were identified. Relevant scientific publications or abstracts presented at peer-reviewed conferences were requested from drug manufacturers.
These updated recommendations focus on adults (Ն18 years) with or at risk for HIV infection in settings in which most antiretroviral drugs are available or in late-stage development (new drug application filed). Recommendations were made by consensus and rated according to strength of the recommendation and quality of the evidence ( Table 1) . For recommendations that have not changed substantially or for which few new data have become available since 2016, the prior report should be reviewed. 1 Details about the development process, panel, evidence collection and literature searches, and sponsor (IAS-USA) and its policies are reported in the Supplement.
When to Start
Recommendations for initiating antiretroviral therapy (ART) are summarized in Box 1. In patients with established HIV, ART should be initiated as soon as possible after diagnosis. 1 The question of when to start ART is focused now on whether immediate ART (same day to 14 days after diagnosis) is preferred. The World Health Organization endorsed ART initiation within 7 days of new diagnosis (including same day), citing improved viral suppression. 4 Rapid initiation of ART requires improving linkage to care and addressing structural barriers (eg, staffing and services availability) within clinics and ART distribution systems.
Rapid ART Start
Randomized trials in Lesotho, Haiti, and South Africa showed significant improvements in viral load suppression at 10 or 12 months and retention in care with rapid initiation of therapy. [5] [6] [7] In 1 study, individuals were randomized to early ART with simplified counseling and point-of-care CD4 cell assays or to standard care. In the intervention group, 80% began ART within 14 days and 71% started ART the same day of eligibility, compared with 38% and 18%, respectively, in the control group. Virologic suppression at 1 year was improved in the intervention group (85% vs 75%). 8 Several cohorts examined the feasibility, outcomes, and challenges of rapid ART start. 9 Meta-analyses of 8 cohorts showed an improvement in the proportion of patients starting ART within 3 months but no benefit on retention in care. 10 A statistically nonsignificant trend toward worse viral suppression was observed for those who started ART rapidly in 1 cohort. 10 San Francisco implemented a citywide rapid ART program in which newly diagnosed persons were linked to care within 5 days from diagnosis and offered treatment on the day of their clinic visit. Of 265 newly diagnosed persons, 97% were linked to care (30% within 5 days) and 81% started ART; time from diagnosis to HIV RNA level below 200 copies/mL decreased by more than 50% and time from first care visit to ART decreased from 27 days to 1 day. 11, 12 A large HIV clinic in Atlanta implemented rapid access to ART on the day of the initial visit. Median time from initial diagnosis to HIV-1 RNA level below 200 copies/mL decreased from 67 to 41 days; however, the program was not sustainable because of increased patient load and inadequate funding for staffing. 13 Despite the success of rapid ART initiation in some settings, starting ART on the day of diagnosis requires coordination between testing and treatment settings and access to resources that may limit treatment uptake. All elements of conventional treatment initiation must be in place at the treatment site but provided in a way that ensures immediate access. 12 ART initiation, including rapid start, is recommended for all infected ambulatory patients committed to starting ART (unless the patient has symptoms that suggest an opportunistic infection for which immediate ART is contraindicated) or for those with unclear HIV diagnosis (eg, discordant serologic or rapid test results) (evidence rating AIII). Because of concerns about transmitted drug resistance (eg, K103N mutation), immediate ART should not be nonnucleoside reverse transcriptase inhibitor (NNRTI)-based (evidence rating AIII). Dolutegravir/tenofovir alafenamide (TAF) (or tenofovir disoproxil fumarate [TDF])/ emtricitabine (or lamivudine) or bictegravir/TAF/emtricitabine or boosted darunavir TAF (or TDF)/emtricitabine (or lamivudine) are recommended for rapid initiation (AIII). Patients requiring abacavir should not begin until the result of testing for the HLA-B*5701 allele is available (evidence rating AIa).
When to Start ART in the Setting of Active Opportunistic Infections and Malignancies
Recommendations for initiating ART in the setting of active opportunistic infections (OIs) remain unchanged. 1 ART should be started within the first 2 weeks after diagnosis for most OIs (evidence rating AIa). Data further support the recommendation to start ART within the first 2 weeks of initiation of tuberculosis treatment for patients with CD4 cell counts below 50/μL and within the first 2 to 8 weeks for those with CD4 cell counts of 50/μL and above (evidence rating AIa). For patients with cryptococcal meningitis in highresourced settings with access to optimal antifungal therapy, frequent monitoring, and aggressive management of intracranial pressure, ART should begin within 2 weeks of diagnosis. 14, 15 Careful monitoring for immune reconstitution inflammatory syndrome is essential. For individuals diagnosed with HIV and a malignancy concurrently, ART should be initiated immediately. 3 Early adverse effects of ART can be monitored and managed while cancer staging and molecular testing are performed.
Primary OI Prophylaxis
With ART universally recommended, the incidence of Pneumocystis pneumonia and major AIDS-associated OIs has declined to less than 1.45 and 0.4 per 100 person-years, respectively, in the United States. 16 For individuals with viral suppression while taking ART, the incidence and overall mortality of Mycobacterium avium complex disease is sufficiently low 17, 18 that primary Mycobacterium avium complex prophylaxis is no longer recommended (evidence rating AIIa). Primary prophylaxis for Pneumocystis pneumonia is still recommended for patients meeting CD4 criteria (evidence rating AIa). 17, 19 Primary prophylaxis for cryptococcal disease is not recommended in settings where incidence is low (evidence rating AIII).
Recommended Initial Regimens
Recommendations for initial ART are summarized in Box 2. Regimens that do not require boosting with ritonavir or cobicistat are favored. Choosing a combination with a high barrier to resistance is important, particularly for individuals with inconsistent adherence. As more generic ART medications become available, cost and access to medications are likely to be of increasing importance (see below). Regimens are also listed for patients who cannot take the generally recommended initial regimens owing to anticipated problems with adherence, drug interactions, patient preference, financial considerations, or lack of availability of recommended options.
Recommended initial ART for most patients is listed in alphabetic order by integrase strand transfer inhibitor (InSTI) component (see also Table 2 for medications and their associated advantages and disadvantages). Bictegravir and dolutegravir do not require pharmacologic boosting, have a high barrier to resistance, and are part of regimens with a low pill burden and toxicity. Studies of these drugs in initial regimens have shown comparable efficacy and no emergence of resistant virus. 20, 21 There are substantially more data and longer-term experience with dolutegravir (approved in the United States in 2013) than with bictegravir (approved in 2018). Preliminary data have raised concerns regarding use of dolutegravir (and potentially other InSTIs) for individuals capable of becoming pregnant (see below). Raltegravir is well tolerated and has fewer drug interactions than other InSTIs but has a lower barrier to resistance and a higher pill burden. Elvitegravir regimens also have a lower barrier to resistance and include a pharmacologic booster (cobicistat) that results in more drug interactions.
In combination with 2 nucleoside reverse transcriptase inhibitors (NRTIs), the NNRTIs efavirenz and rilpivirine each demonstrate high rates of virologic suppression as initial therapy. Efavirenzbased treatment was standard initial therapy for many years, but studies have demonstrated higher rates of adverse effects (rash and central nervous system adverse effects) than InSTI-based therapy. Rilpivirine has a lower rate of central nervous system adverse effects and rash than efavirenz and is coformulated with TAF/ emtricitabine into the smallest single tablet for initial therapy. However, rilpivirine must be taken with food, requires stomach acidity ART should be initiated as soon as possible after diagnosis, including immediately after diagnosis, unless patient is not ready to commit to starting therapy (evidence rating AIa).
Structural barriers that delay receipt of ART should be removed to allow newly diagnosed persons to receive ART at the first clinic visit after diagnosis, if they and their clinician determine that this approach is appropriate (evidence rating AIa).
Samples for HIV-1 RNA level; CD4 cell count; HIV genotype for NRTI, NNRTI, and PI; laboratory tests to exclude active viral hepatitis; and chemistries should be drawn before beginning ART, but treatment may be started before results are available. Result of testing for HLA-B*5701 allele should be available if an abacavir-containing regimen is anticipated (evidence rating AIa).
NNRTIs and abacavir should not be used for rapid ART start (evidence rating AIII).
ART should be started as soon as possible but within the first 2 weeks after diagnosis for most OIs (evidence rating AIa).
Primary MAC prophylaxis is no longer recommended if effective ART is initiated (evidence rating AIIa).
Primary prophylaxis for Pneumocystis pneumonia should be initiated for patients with CD4 cell counts below 200/μL (evidence rating AIa).
Prophylaxis for cryptococcal disease is not recommended in highly resourced settings with low prevalence of disease (evidence rating AIII).
ART should be implemented immediately in the setting of newly diagnosed malignancy, with attention to drug-drug interactions (evidence rating BIIa).
for adequate absorption, and is recommended only for patients with baseline HIV RNA level below 100 000 copies/mL and CD4 cell count above 200/μL. The NNRTI doravirine is currently under investigation for initial therapy. In phase 3 trials, doravirine was noninferior to efavirenz and to ritonavir-boosted darunavir in achieving virologic suppression and had fewer central nervous system adverse events than efavirenz and a better lipid profile than either efavirenz or ritonavir-boosted darunavir.
22,23 Thus, doravirine may be preferable to existing NNRTIs, but no prospective studies compare it with InSTI-based regimens. Non-InSTI initial regimens are summarized in Table 3 .
Abacavir is a component of the recommended regimen dolutegravir/abacavir/lamivudine. Individuals who test positive for the HLA-B*5701 allele are at risk of a potentially life-threatening hypersensitivity reaction to abacavir. 1 Results of HLA-B*5701 testing must be available before use (evidence rating AIa); patients who test positive should not be given abacavir (evidence rating AIa), and this information should be documented in the medical record.
Although some prior comparisons of abacavir/lamivudine and TDF/emtricitabine demonstrated an efficacy advantage of TDF/ emtricitabine in patients with high HIV-1 RNA levels, 1 the differences have not been observed in studies that use InSTIs. 20 Abacavir has no activity against hepatitis B virus (HBV) and should not be used in patients with HIV and HBV.
TAF-and TDF-containing regimens are similar virologically. Compared with TDF, TAF results in a lower plasma level of tenofovir and higher intracellular concentration of the active antiviral component tenofovir diphosphate. This results in fewer tenofovirassociated renal and bone toxic effects. 25 These differences between TAF and TDF are accentuated when TDF is used with ritonavir or cobicistat, which increase tenofovir plasma levels.
26

Two-Drug Initial Therapy
Initial 2-drug regimens are under investigation. This strategy may offer cost or toxicity advantages over standard 3-drug regimens, but efficacy needs to be confirmed. 27 Darunavir/ritonavir plus raltegravir was noninferior to darunavir/ritonavir plus 2 NRTIs, but the 2-drug regimen had higher rates of treatment failure in patients with a CD4 cell count below 200/μL or an HIV RNA level above 100 000 copies/mL.
28
Dolutegravir plus lamivudine and darunavir/ritonavir plus lamivudine are being studied. 29, 30 Until further data are available, initial 2-drug regimens are reserved for the rare situation when individuals cannot take abacavir, TAF, or TDF. In this situation, darunavir/ritonavir plus raltegravir (if <100 000 HIV RNA copies/mL and CD4 cell count >200/μL) or darunavir/ritonavir plus lamivudine may be used (if there is no lamivudine resistance) (evidence rating BIa). Short-term data from comparative trials may provide support for dolutegravir plus lamivudine as initial 2-drug therapy (NCT02831764). Dolutegravir plus rilpivirine has not yet been assessed for initial therapy.
31
Unique Considerations
Pregnancy Individuals who are pregnant should initiate ART as soon as possible for their own health and to reduce transmission to the infant (evidence rating AIa). 1 The NRTI options include abacavir/ lamivudine (or emtricitabine) if patient tests negative for HLA-B*5701 or TDF/emtricitabine (or lamivudine). Insufficient safety data for TAF preclude use of this drug during pregnancy.
A preliminary report revealed neural tube defects among infants born to women taking a dolutegravir-containing regimen at conception, suggesting, for now, that dolutegravir should be avoided in individuals of childbearing age who wish to become pregnant, are trying to get pregnant, or are sexually active and not reliably using contraception. 32 All individuals of childbearing age should have documentation of a negative pregnancy test result before starting dolutegravir and should be counseled regarding this potential risk. More data are expected; it is not yet clear whether other InSTIs pose a similar risk of neural tube defects.
Raltegravir is the recommended InSTI for individuals who are already pregnant. Elvitegravir/cobicistat should not be used during pregnancy (evidence rating AIIa). Pregnant women already taking elvitegravir/cobicistat should be switched to a recommended regimen. 33 Bictegravir should not be used during pregnancy because available safety data are insufficient.
Recommended protease inhibitors (PIs) include atazanavir/ ritonavir (once daily) or darunavir/ritonavir (twice daily). Drugs boosted with cobicistat (eg, darunavir/cobicistat and atazanavir/ cobicistat) are not recommended for use during pregnancy because of pharmacokinetic concerns or insufficient data (evidence rating AIIb).
32 Efavirenz and rilpivirine are alternatives in pregnancy. There were initial concerns regarding potential neural tube defects with efavirenz, but accumulated data now support the safety of efavirenz during pregnancy.
HBV and Hepatitis C Virus Co-infection
HIV-infected patients with HBV co-infection should initiate an ART regimen that contains TDF or TAF (evidence rating AIa), lamivudine or emtricitabine, and a third component. [34] [35] [36] Patients with HIV co-infected with hepatitis C virus (HCV) are candidates for HCV treatment and therefore should start an ART regimen with drugs that have minimal drug interactions with HCV therapies (evidence rating AIIa), such as dolutegravir/abacavir/lamivudine, dolutegravir/TAF/ emtricitabine, bictegravir/TAF/emtricitabine, or raltegravir plus TAF/ emtricitabine. Clinicians should consult current HCV treatment guidelines (https://www.hcvguidelines.org).
Bone, Kidney, and Cardiovascular Disease HIV is associated with osteoporosis and fractures. 37 Baseline bone mineral density testing is recommended in postmenopausal women and in anyone older than 50 years (evidence rating BIII). During the first 1 to 2 years after ART initiation, patients may lose 2% to 6% of bone mineral density at the hip and spine. Patients taking TDF-containing regimens have a greater initial decline in bone mineral density than those who take a TAF-or abacavir-containing regimen. 1, 20, 38 Accordingly, TDF is not recommended for patients with osteopenia or osteoporosis (evidence rating BIII). Abacavir does not require dose adjustment based on renal function. TAF can be used if creatinine clearance is above 30 mL/min/1.73 m 2 (evidence rating AIIa).
1 Dose reduction of lamivudine is recommended for patients with creatinine clearance below 50 mL/min/1.73 m 2 . There are data supporting use of elvitegravir/cobicistat/TAF/emtricitabine once daily in patients with end-stage renal disease (estimated glomerular filtration rate <15 mL/min) receiving long-term hemodialysis.
39
HIV-infected patients with end-stage renal disease should be evaluated for kidney transplantation (evidence rating AIIa). The association between abacavir use and increased risk of myocardial infarction remains controversial. 1, 40 Given the uncertainty, abacavir should be used with caution or avoided in patients who have or are at high risk for cardiovascular disease.
Recommended Initial ART in the Setting of OIs and Malignancies
Choice of ART regimen in the setting of OIs and malignancies is guided by drug-drug interactions with the antimicrobial or chemotherapy regimen. Unboosted InSTI-based regimens are recommended. In the setting of malignancy, OI prophylaxis should be instituted, regardless of CD4 cell count, according to specific chemotherapy regimens used.
The recommended regimens for initial ART in the setting of rifamycin-based antituberculosis therapy are 2 NRTIs (excluding TAF) plus efavirenz (600 mg daily), raltegravir (800 mg twice daily), or dolutegravir (50 mg twice daily) (evidence rating AIa).
1,41 Coadministration of bictegravir (along with TAF/emtricitabine) twice daily with rifampin for 28 days is not recommended, owing to significantly decreased area under the curve (AUC) and peak serum concentration after administration (C max ) for bictegravir (evidence rating AIIa).
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When TAF is administered with rifampin, plasma TAF C max and AUC as well as intracellular tenofovir diphosphate levels were decreased; however, intracellular tenofovir diphosphate concentrations were higher than those achieved with standard-dose TDF. Further evaluation of TAF in tuberculosis co-infection is under way. 43 Boosted PIs should be used only if an efavirenz-or InSTI-based regimen is not an option, and rifabutin (150 mg daily) should be substituted for rifampin in the antituberculosis regimen (evidence rating AIa). 1 For latent tuberculosis, a 1-month course of daily rifapentine plus isoniazid was equivalent to 9 months of isoniazid in persons with HIV. 44 Daily rifapentine can be safely administered with efavirenzbased ART. Once-weekly rifapentine/isoniazid is also safe, welltolerated, and has an acceptable pharmacokinetic profile when used with raltegravir. Dolutegravir-based regimens should not be used with rifapentine/isoniazid for treatment or prevention of tuberculosis, pending further evaluation.
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When and How to Switch
Recommendations for when and how to switch ART regimens are summarized in Box 3. The most common reasons for switching therapy are regimen simplification, newly diagnosed comorbidities (or to prevent comorbid conditions), and management of interactions with drugs or supplements. In addition to these reasons, a regimen switch may be required to minimize the patient's insurance co-payments or to satisfy payer formulary requirements.
Switching from older antiretroviral regimens should be considered when there is evidence of or potential for chronic toxicity, drug-drug interactions, or emergent adverse effects with current regimens. 1, 31, 46 Proactive switching from TDF-to TAF-containing regimens to minimize renal or bone adverse effects may be beneficial. 47 Care should be taken when switching from regimens boosted with ritonavir to ones boosted with cobicistat because of different drug-drug interactions. 48 In patients without a history of treatment failure, data support switching from regimens containing TDF to single-tablet regimens including dolutegravir/abacavir/lamivudine, 46 Simplification from a boosted PI 53 or from emtricitabine/TAF plus dolutegravir 54 to a single-tablet bictegravir/emtricitabine/TAF regimen maintained viral suppression above 90%. Switching to 2 antiretroviral drugs has been used to reduce NRTI-related bone, kidney, and cardiovascular complications and cost. Dolutegravir/ rilpivirine maintained virologic suppression in patients with no previous virologic failure or evidence of resistance who switched from a 3-drug ART regimen.
31 Dual-therapy regimens that include a boosted PI (lopinavir, atazanavir, or darunavir) and lamivudine were noninferior to 3-drug regimens in maintenance of virologic suppression up to 2 years.
55-57 Dolutegravir and lamivudine maintained virologic suppression to 48 weeks among patients with no prior virologic failure or transmitted NRTI resistance. 58, 59 Fewer options exist for regimen simplification in virologically suppressed individuals in whom several previous regimens have failed over time. Preexistent NRTI and NNRTI mutations were associated with viral rebound after switching to rilpivirine/emtricitabine/TDF.
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Darunavir/cobicistat/emtricitabine/TAF maintained virologic suppression in patients switching from a boosted PI plus emtricitabine/TDF, even if there was previous virologic failure, provided there was no history of darunavir failure or darunavir-resistance mutations.
51
Elvitegravir/cobicistat/emtricitabine/TAF combined with darunavir taken once daily effectively maintained virologic suppression in patients with 2-class drug resistance (up to 3 thymidine analogueassociated mutations but no multi-NRTI or darunavir mutations) while taking multidrug regimens.
61
Monotherapy with PIs or InSTIs as a maintenance strategy is not recommended because of higher rates of virologic rebound, 1, [62] [63] [64] [65] often with resistant virus (evidence rating AIIb).
62,63
Virologic Failure
Virologic failure is increasingly uncommon with currently recommended ART regimens. Exploration for reasons of inconsistent adherence, drug-drug interactions, and collation of all resistance mutations identified by genotype, along with the ART history, are required to select a new treatment regimen.
For failure of an initial NNRTI-based regimen, dolutegravir plus NRTIs was superior to lopinavir plus NRTIs when the next regimen included at least 1 active NRTI. 66 For failure of initial PI-based or InSTI-based therapy (without resistance), boosted PI-or dolutegravirbased therapy with 1 or 2 fully active NRTIs should be effective.
For virologic failure after initial raltegravir-or elvitegravir-based regimens with the presence of integrase mutations, dolutegravir (50 mg twice daily) with at least 1 other active drug may be effective, but clinical data are lacking. 1 For virologic failure with more complex treatment history, therapy with at least 2 fully active drugs from • Review of the ART treatment history, regimen tolerability, comedications, and results of prior resistance tests is recommended before any treatment switches are made (evidence rating AIa).
• In patients with NRTI mutations, switching from a boosted PI to a regimen containing a drug with a low genetic barrier to resistance (eg, NNRTI or raltegravir) is not recommended (evidence rating AIa).
• HIV viral load should be checked 1 month after switching regimens to ensure virologic suppression has been maintained (evidence rating BIII).
Switching When Virologically Suppressed
• Patients taking older ART drugs with known toxicity should be questioned carefully to identify subtle adverse effects of which they may be unaware or that they may not attribute to the drug.
The presence of these toxicities should prompt a change in regimen (evidence rating BIII).
• In general, if the older regimen is well tolerated without evidence of toxicity, there is little reason to switch to a newer regimen (evidence rating BIII).
• Proactive switching from TDF to TAF is recommended for patients at high risk of renal or bone toxicity (evidence rating BIa). Review of comedications is essential to ensure no change in dosing is required with the use of TAF.
• Switching from 3-drug regimens to certain 2-drug regimens in the setting of viral suppression, using dolutegravir/rilpivirine (evidence rating AIa), a boosted PI with lamivudine (evidence rating AIIa), or dolutegravir with lamivudine (evidence rating AIIa) can be used in patients with no prior virologic failure or transmitted drug resistance. (Longer-term follow-up is needed to confirm the durability of these strategies).
• Patients who are co-infected with HIV and HBV should receive a regimen that contains 2 drugs active against HBV, usually TAF or TDF plus lamivudine or emtricitabine, in addition to a third ART drug (evidence rating AIIa). Such patients should generally not be switched to 2-drug ART.
• Monotherapy with boosted PIs or dolutegravir is not recommended (evidence rating AIIa).
Switching for Virologic Failure
• Resistance testing is recommended while taking the failing ART regimen or within 4 weeks of stopping (evidence rating AIIa).
• Virologic failure should be confirmed and, if resistance is identified, a prompt switch to another active regimen using results of current and past resistance testing to prevent accumulation of additional resistance mutations is recommended (evidence rating BIIa).
• Dolutegravir, plus 2 NRTIs (with at least 1 active by genotype) is recommended after initial treatment failure with an NNRTI (evidence rating AIa).
• A boosted PI plus 2 NRTIs (with at least 1 active NRTI) are recommended for initial treatment failure of an InSTI-containing regimen (evidence rating AIII).
• Dolutegravir plus at least 1 fully active other agent may be effective in the setting of raltegravir or elvitegravir resistance. Dolutegravir should be dosed twice daily in this setting (evidence rating BIII).
• A single active agent added to a failing regimen is not recommended (evidence rating AIa).
• For multiclass resistance, the next regimen should be constructed using drugs from new classes if available (evidence rating BIII).
Abbreviations: ART, antiretroviral therapy; HBV, hepatitis B virus; NNRTI, nonnucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate. Ibalizumab, an anti-CD4 monoclonal antibody that inhibits HIV cell entry via CD4 binding, is active against CCR5-and C-X-C chemokine receptor 4 (CXCR4)-tropic HIV isolates and may be useful as a fully active agent for patients with multiclass-resistant virus (evidence rating BII). Almost 50% of adults with virologic failure from multidrug-resistant HIV achieved undetectable HIV RNA levels at 24 weeks after receipt of biweekly intravenous ibalizumab (800 mg) with at least 1 other active drug.
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults
67,68
Laboratory Monitoring
Recommendations for laboratory monitoring are summarized in Table 4 and Box 4. All individuals who have ever been sexually active should be tested for HIV at least once in their lives (evidence rating AIII). Risk for HIV often changes over a person's lifetime; risk evaluation is recommended at each routine clinical visit (evidence rating AIII). For men who have sex with men (MSM), transgender women, people who inject drugs, and others with increased risk, testing is recommended at least annually and perhaps as frequently as every 3 months (evidence rating BIII).
69 Diagnosis of sexually transmitted infections (STIs) and HCV can help identify individuals who should be tested more regularly for HIV and who might benefit from preexposure prophylaxis (PrEP) (evidence rating BIII).
70-72 Testing performed with assays that measure HIV antibody and antigen is recommended because it can take 3 weeks or longer for HIV antibodies to be detected after initial infection. In contrast, HIV RNA or combination antibody with p24 antigen tests that can detect HIV within 10 to 14 days after infection are recommended (evidence rating AIIa). 73 Relying on symptoms of the acute retroviral syndrome to trigger testing will miss infections because acute infection may be asymptomatic. 1, 74, 75 Available home-based HIV tests do not detect acute HIV infection but can be useful for people without access to testing otherwise. 76 All available tests can have false-positive results, so confirmatory measurement of HIV RNA level is recommended before ART initiation, although treatment can be initiated before results are available (evidence rating AIa).
Before starting ART, recommended laboratory monitoring includes HIV RNA level, CD4 cell count, and reverse transcriptase and protease genotype (InSTI genotyping generally is not recommended because it is not cost-effective) 77 ; general health (testing for kidney/liver function, lipid levels, complete blood cell count, glucose level, and pregnancy status); and co-infections (hepatitis A, B, and C, tuberculosis, and STIs) (evidence rating AIa). Unless preexisting kidney or liver damage or high likelihood of transmitted drug resistance exists, the results of these tests should not delay start of ART (evidence rating BIII). [78] [79] [80] [81] Testing for CCR5 tropism is recommended each time when considering maraviroc, and HLA-B*5701 testing (only needed once) is recommended before starting abacavir (evidence rating AIa).
Monitoring During ART
Within 6 weeks of starting ART, adherence and tolerability of therapy should be assessed, along with HIV RNA level. HIV RNA suppression may take up to 24 weeks, or faster with InSTI-based regimens. 1, 82 Once the HIV RNA level is below 50 copies/mL, monitoring is recommended every 3 months until suppressed for at least 1 year. After that year, monitoring can be performed every 6 months if the patient maintains consistent medication adherence (evidence rating AIII). Of note, when monitoring intervals are extended and therapy fails, resistance has more time to emerge.
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Once viral suppression occurs with ART, CD4 cell counts usually increase.
1,83 CD4 measurements are recommended every 6 months until above 250/μL for at least 1 year with concomitant viral suppression (evidence rating BIII). 1, 84 Afterward, CD4 cell counts need not be measured unless ART fails (defined below) or the patient has an immunosuppressive condition or treatment, such as steroid treatments or chemotherapy (evidence rating AIII). 85 Patients taking ART should have regular clinical and laboratory evaluations, including age-and risk-appropriate screening.
HIV RNA testing is used to detect if ART is failing. When HIV RNA level is above 50 copies/mL, repeating measurement of HIV RNA level within 4 weeks and reassessing for medication adherence and tolerability is recommended (evidence rating AIIb). Virologic failure is defined as HIV RNA level above 200 copies/mL on at least 2 consecutive measurements. Once virologic failure is diagnosed, an HIV genotype should be obtained while the patient is taking the failing regimen. 1 If HIV genotyping is unsuccessful (eg, HIV RNA level is <1000 copies/mL), a proviral DNA analysis using deep sequencing methods may be used. 86 For virologic failure of InSTIcontaining ART, integrase resistance testing is recommended (evidence rating AIII).
1,87-89 Once a new regimen is started, HIV RNA level should be checked 4 to 6 weeks after initiation, following the same schedule as for monitoring of initial therapy (evidence rating AIII). 1 Optimal care for patients with persistent viremia between 50 and 200 copies/mL is unclear. The ART regimen should be continued, with assessment of medication adherence (evidence rating BIII). There is no indication to intensify the regimen with additional antiretrovirals. 90 Engagement in Care and ART Adherence
Recommendations for engagement in care and ART adherence are summarized in Box 5. The HIV care continuum provides a framework to enhance individual health outcomes and maximize the benefits afforded by treatment as prevention. In the setting of sustained viral suppression, individuals with HIV do not transmit HIV to sexual partners (described as "undetectable = untransmissable" [U = U]). 91, 92 In the United States, 22% of initial HIV diagnoses occur within 3 months of an AIDS diagnosis, indicating that persons are entering HIV care late. 93 Clinicians not offering HIV testing in emergency departments and acute medical care settings appears to be a major limitation in early diagnosis of HIV. 94 Monitoring successive steps on the HIV care continuum helps address barriers that impede initial linkage, subsequent retention, and successful reengagement of patients lost to care.
1 Missed medical care visits can be assessed in real time and are consistently associated with poor HIV outcomes. 95 Assessment of missed visits in the prior year predicts future risk for missing future appointments, allowing for clinic-level intervention. 96 Coordination of appointment data with public health surveillance systems (eg, "Data to Care") enhances linkage to, and retention and reengagement in, care.
97,98
Resource-intensive interventions among vulnerable individuals (eg, those hospitalized or with substance use disorders) have yielded modest short-term improvements in care engagement and viral suppression.
99,100 Cash incentives to encourage adherence with treatment and follow-up do not work consistently and generally are not recommended (evidence rating AIa).
99,101 However, noncash incentives as part of combination strategies are effective.
102,103 Tiered strategies using risk stratification to identify high-acuity patients are recommended (evidence rating CIIb), as is providing low-threshold medical care, such as open access (ie, "walk in") clinics, integrated with high-intensity outreach implemented in conjunction with public All persons who have ever been sexually active should be tested for HIV at least once in their lives (evidence rating AIII).
Risk for HIV often changes over a person's lifetime; risk evaluation is recommended at each routine clinical visit (evidence rating AIII).
For sexually active men who have sex with men and for transgender women, people who inject drugs, and others at increased risk, testing is recommended at least annually and as frequently as every 3 months (evidence rating BIII).
Diagnosis of sexually transmitted infections and hepatitis C virus can help identify persons who should be tested more regularly for HIV and who might benefit from preexposure prophylaxis (evidence rating BIII).
HIV screening with assays that can detect recent HIV infection, either an instrument-based combination antigen/antibody assay or a combination of a stand-alone antibody assay and nucleic acid testing, is recommended (evidence rating AIIa).
Persons with ongoing condomless sexual exposures or sharing of needles or works need to be tested with assays that can detect HIV RNA or with combination antibody + p24 antigen tests (evidence rating AIIa). Individuals with signs or symptoms of acute or primary HIV infection should be tested with HIV RNA assays.
All available tests can have false-positive results, so additional testing with an HIV viral load is recommended before ART initiation, although treatment may be started before results are available (evidence rating AIa).
HIV genotype to assess transmitted NRTI and NNRTI resistance should be performed; InSTI genotyping at baseline is not recommended unless exposure to a partner with InSTI resistance is suspected (evidence rating BIII).
CCR5 tropism testing is recommended each time when considering maraviroc and HLA-B*5701 testing (only needed once) before use of abacavir (evidence rating AIa).
Once HIV RNA level is below 50 copies/mL, monitoring is recommended every 3 months until virus is suppressed for at least a year. After 1 year of viral suppression, monitoring can be reduced to every 6 months if the patient maintains consistent medication adherence (evidence rating AIII).
Measurement of CD4 cell counts is recommended every 6 months until cell counts are above 250/μL for at least 1 year with concomitant viral suppression (evidence rating BIII).
Age-and risk-appropriate screening for STIs at various anatomical sites, anal or cervical dysplasia, tuberculosis, general health, and medication toxicity is recommended (evidence rating AIII).
Once a viral load above 50 copies/mL is detected, measurement should be repeated within 4 weeks, and reassessing for medication adherence and tolerability is recommended (evidence rating AIII).
Measurement of viral load at 4 to 6 weeks after starting a new ART regimen is recommended (evidence rating AIII).
If the viral load has not declined, adherence and toxicity should be discussed with the patient. If adherence appears to be sufficient, a genotype assay is recommended (evidence rating AIII). health agencies, jails, housing, and mental health case management (evidence rating CIII).
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Guidelines exist for ART adherence monitoring and interventions.
105 Systematic screening for ART medication adherence via patient self-report using validated instruments or using pharmacy refill measures, and not relying solely on plasma viral load, is recommended.
1 Individuals with suboptimal adherence should be assessed for inadequate housing, 106-108 food insecurity, 109-111 active substance use, 110 psychiatric disorders, medication adverse effects, and pill burden.
Internalized stigma, defined as a patient's negative feelings or thoughts related to their HIV status, and depression are associated with poor medication adherence, visit retention, and clinical outcomes.
112-114 Chronic depression increases the risk for missed clinic visits, virologic failure, and a 2-fold increase in mortality risk. 115 Treatment with antidepressants can improve virologic suppression, CD4 cell counts, and remission from clinical symptoms. 116 
Cost
From the patient perspective, the most relevant cost is the out-ofpocket expense of accessing treatment. The payer perspective is to use the lowest-cost medications to avoid the most expensive and severe HIV outcomes (eg, hospitalizations). The latter perspective often places greater value on immediate costly outcomes rather than prevention of events occurring remotely in time (eg, renal or cardiovascular toxicity). For example, a patient and clinician might value the renal and bone safety of TAF over that of TDF, but the payer might determine that the similar virologic efficacy does not justify the higher cost of TAF.
117
The societal perspective considers the cost and outcomes for all parties involved. Since this perspective does not favor one group over another, it is adopted by most cost-effectiveness analyses for which therapies are considered in relation to each other, with the one providing the greatest return on investment being preferred. For example, despite its high cost, the benefits of ART are so large it is considered cost-effective.
118-120
The availability of more generic antiretrovirals and the use of 2-drug regimens could reduce the costs of treatment substantially. Generic antiretrovirals have already reduced the cost of HIV treatment globally, allowing millions of patients to be treated in resourcelimited settings. In developed countries, many antiretroviral agents and coformulations are available as lower-cost generics. Limitations include a forced switch from branded coformulated regimens to separate pills 121, 122 ; more pharmacy co-pays for separate prescriptions; use of older agents that are not part of current recommended regimens; and high costs if an insufficient number of generic manufacturers enter the market. However, a modeling study found that use of a partially generic regimen including multiple pills would be highly cost-effective. 123 Ultimately, the first priority for clinicians and patients is to find the most effective and safest treatment. If multiple options exist with similar outcomes, choosing the lowest-cost options makes intuitive sense, provided there are no additional patient cost barriers.
Prevention
Recommendations for the prevention of HIV infection are summarized in Box 6. Use of antiretrovirals for HIV prevention spans 3 domains: treatment as prevention, prophylaxis for currently uninfected individuals (PrEP and postexposure prophylaxis [PEP]), and prevention of mother-to-child transmission.
As noted, maintaining U = U status requires continued viral suppression. There are 2 caveats to consider when counseling patients about U = U: The only transmissions that occurred in studies happened early after starting treatment and 3 to 6 months of viral suppression may therefore be required; and durable viral suppression cannot be assessed based on a single measurement. 124 Importantly, transmission Routine, opt-out HIV screening is recommended in primary medical care settings, emergency departments, and for all pregnant women (evidence rating AIIa).
Routine screening and treatment for depression is recommended (evidence rating AIIa).
Systematic monitoring of time to care linkage after initial HIV diagnosis, retention in care, reengagement in care, ART adherence, and rates of viral suppression is recommended in all care settings and at a population level (evidence rating AIIa).
Brief, strengths-based case management is recommended after HIV diagnosis to facilitate linkage to care (evidence rating AIa).
Systematic monitoring of missed clinic visits and rapid intervention after a missed visit is recommended (evidence rating AIIa).
Personal telephone and interactive text reminders in advance of scheduled appointments and shortly after missed appointments (eg, 24-48 hours) are recommended (evidence rating AIa).
Adherence monitoring using patients' self-report obtained by validated adherence instruments and pharmacy refill data is recommended (evidence rating AIIa).
Integration of directly observed ART in methadone maintenance programs (evidence rating BIa) and as a treatment strategy among persons with substance use disorders (evidence rating BIa) and those who are incarcerated or released to the community (evidence rating CIII) is recommended to enhance adherence and viral suppression.
Opioid substitution therapy for opioid-dependent patients is recommended (evidence rating AIa).
Rapid HIV test algorithms may be used to confirm a preliminary positive rapid test result, allowing for same-day referral to treatment from nonclinical settings (evidence rating AIa).
Use of public health surveillance in conjunction with clinic-level data to guide individual-level linkage and reengagement in care activities is recommended (evidence rating BIIa).
Cash financial incentives for clinic appointment attendance and achievement of viral suppression are generally not recommended as a retention-in-care strategy (evidence rating AIa).
Data-driven risk stratification to identify high-acuity, high-need patients for combination intervention strategies to improve care engagement and viral suppression is recommended (evidence rating CIIb).
Screening for and addressing housing instability, food insecurity, ongoing substance use, psychiatric disorders, medication adverse effects, and pill burden is recommended (evidence rating BIIa).
Abbreviation: ART, antiretroviral therapy.
can occur when an HIV-seronegative partner in a serodiscordant relationship has partners outside of that relationship. Guidelines exist for occupational (needle stick and fluid splash to mucous membranes) 125 and nonoccupational (sexual-and injection-drug related) PEP.
126 PEP should be started as soon as possible after a potential exposure to maximize effectiveness.
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Abacavir-based PEP is not recommended unless the exposed patient is known to be HLA-B*5701 negative (evidence rating AIII). Available data are insufficient to recommend TAF-based regimens for PEP.
PrEP with TDF/emtricitabine is highly effective in preventing HIV acquisition from sexual exposures.
1 TDF alone prevented infection in people who inject drugs, but TDF/emtricitabine is recommended for these persons. Substance use and medical histories (particularly renal and bone disease) are important in deciding whether to provide PrEP to best balance potential risks and benefits. PrEP is recommended for populations with an HIV incidence above 2% per year (evidence rating AIII) and for HIV-seronegative partners of HIV-infected persons who are not consistently virally suppressed.
127,128 Unlike condoms, PrEP does not prevent other STIs. For people who inject drugs, clean injection equipment and access to substance use treatment should be available.
Daily TDF/emtricitabine is recommended for persons at risk of HIV through sexual exposure (evidence rating AIa) and for people who inject drugs (evidence rating BIa). 1 Daily dosing is required for optimal protection.
129 This is especially important for women, given that tenofovir concentrates at 10-fold lower levels in vaginal tissue than in rectal tissue and clearance is faster.
130
On-Demand or Event-Driven PrEP ("2-1-1") Pericoital TDF/emtricitabine, known as on-demand or eventdriven PrEP, is effective for HIV prevention among MSM and an alternative to daily PrEP for MSM with infrequent sexual exposures (evidence rating AIa). The IPERGAY (Intervention Préventive de l'Exposition aux Risques avec et pour les Gays) study assessed Quarterly screening for asymptomatic STIs is recommended for all populations with high rates of bacterial STIs and incomplete condom use (evidence rating AIIa).
Abacavir-based PEP is not recommended unless the exposed patient is known to be negative for the HLA-B*5701 allele (evidence rating AIII).
PrEP is recommended for populations whose annual HIV incidence is at least 2% (evidence rating AIII).
Daily TDF/emtricitabine is the recommended regimen for men and women (evidence rating AIa) and transgender individuals (evidence rating AIIa) at risk of sexual exposure (evidence rating AIa) and people who inject drugs (evidence rating BIa).
A 1-week lead-in time is recommended with daily dosing for rectal, penile, and vaginal exposures with daily TDF/emtricitabine to ensure adequate tissue levels are achieved (evidence rating CIII).
At PrEP discontinuation, TDF/emtricitabine should continue for 1 week after the last sexual exposure (evidence rating CIII).
For individuals with active HBV infection (detectable HBsAg), discontinuation of TDF/emtricitabine PrEP could lead to acute HBV flares or hepatic decompensation, particularly for patients with hepatic cirrhosis; careful monitoring of HBV infection and liver function is recommended after discontinuation of TDF/emtricitabine (evidence rating AIIa).
Pericoital TDF/emtricitabine PrEP, also known as on-demand, event-driven, or "2-1-1" dosing may be considered as an alternative to daily PrEP for MSM with infrequent sexual exposures (evidence rating AIa). This regimen is not recommended in other risk groups or in patients with active HBV infection because of the risk of hepatitis flare and hepatic decompensation (evidence rating BIIa).
If intercourse is planned in the context of 2-1-1 PrEP regimen, the first (double) dose of TDF/emtricitabine should be taken closer to the 24-hour precoital time than the 2-hour time (evidence rating CIII).
TDF/lamivudine, TAF/emtricitabine, and TDF alone are not recommended for PrEP (evidence rating BIII).
TDF-based PrEP is not recommended in persons with creatinine clearance below 60 mL/min/1.73 m 2 (evidence rating AIIa)
HIV testing, preferably with a combination antigen-antibody assay (evidence rating AIII), to confirm HIV-seronegative status is mandatory at time of initiation of TDF/emtricitabine PrEP; HIV RNA testing should be obtained if acute HIV is suspected.
Measurement of serum creatinine level, determination of estimated glomerular filtration rate, and HBsAg testing are recommended before initiation of PrEP but need not impede PrEP initiation (evidence rating BIII).
During PrEP, intervals of follow-up every 3 months are recommended to allow for HIV testing (evidence rating AIII) and STI screening (evidence rating AIIa).
HCV serologic testing should be performed at least annually and more frequently in the case of elevated transaminase levels or in high-risk individuals (eg, people who inject drugs) (evidence rating BIIa).
PrEP prescription should not exceed 90 days without interval testing for HIV infection (evidence rating AIII); a visit 30 days after PrEP start is recommended for follow-up HIV testing, to assess adverse effects and support adherence (evidence rating BIII).
Measurement of creatinine level should be performed at least every 6 months (evidence rating AIII) and more frequently for some patients (eg, those >50 years, taking hypertension or diabetes medications, or with glomerular filtration rates <90 mL/min) (evidence rating BIIa).
Each PrEP visit should be used to assess and troubleshoot barriers to adherence to PrEP (evidence rating BIII).
For confirmed HIV infection in the setting of PrEP use, a recommended initial antiretroviral regimen should be started, pending results of resistance testing (evidence rating AIII).
For individuals being treated with a course of 3-drug PEP for a recent exposure who are likely to be at risk of ongoing exposure, a seamless transition from PEP to PrEP is recommended (evidence rating CIII).
If during PrEP treatment, exposure to HIV is known to occur, intensification of treatment with additional agent(s) is not recommended (evidence rating BIII).
Abbreviations: HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HCV, hepatitis C virus; MSM, men who have sex with men; PEP, postexposure prophylaxis; PrEP, preexposure prophylaxis; STI, sexually transmitted infection; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate. The 2-1-1 regimen achieved target exposures of tenofovir diphosphate and emtricitabine triphosphate in colorectal tissue at the time of coitus in 81% and 98% of the population when administered 2 and 24 hours before coitus, respectively; target exposure was sustained for the next 10 days.
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130,137-139 If intercourse is planned, the first (double) dose of TDF/emtricitabine should be taken closer to the 24-hour precoital time than the 2-hour time (evidence rating CIII).
Lack of data among heterosexual men and women, transgender men and women, and people who inject drugs precludes recommendation of the 2-1-1 regimen in these populations (evidence rating AIII). The 2-1-1 regimen also is not recommended for patients with active HBV, because of risks of HBV reactivation and HBV resistance (evidence rating BIIa).
Regimen Choice and Laboratory Monitoring
TDF/emtricitabine is the recommended PrEP agent (evidence rating BIII); TDF/lamivudine, TAF/emtricitabine, or TDF alone are not recommended for PrEP at this time (evidence rating BIII). TDFbased PrEP is not recommended for persons with creatinine clearance below 60 mL/min/1.73 m 2 (evidence rating AIIa). Glomerular dysfunction may occur with therapy, particularly in individuals older than 50 years. The dysfunction is usually reversible, and rechallenge with PrEP is often possible.
140 Such patients should have more frequent creatinine clearance monitoring (evidence rating BIIa).
A combination HIV antigen-antibody assay should be performed within 7 days before initiation of TDF/emtricitabine PrEP to exclude HIV infection (evidence rating AIII). An HIV RNA assay may be needed to exclude acute HIV infection in high-risk populations. A 1-month follow-up visit is recommended to assess adherence and tolerability and to ensure the absence of primary HIV infection (evidence rating BIII).
141 Subsequent follow-up is recommended every 3 months to allow for STI screening (urine, throat, anal, and vaginal tests) (evidence rating AIIa) and HIV testing (evidence rating AIII). HCV serologic testing should be performed at least annually and more frequently in high-risk individuals (eg, people who inject drugs) or those with elevated transaminase levels (evidence rating BIIa). PrEP prescription should not exceed 90 days without interval testing for HIV infection (evidence rating AIII). Unanticipated interruptions in PrEP delivery (eg, insurance coverage lapse, incarceration, and relocation) have been associated with seroconversions and should be avoided. 146 For individuals being treated with a course of 3-drug PEP for a recent exposure, who are likely to be at risk of ongoing exposure, a seamless transition from PEP to PrEP is recommended (evidence rating CIII). Given a negative result for a fourth-generation instrumented test (eg, combination HIV antigen-antibody test) at the conclusion of a 28-day PEP course, PrEP with daily TDF/emtricitabine may be initiated or resumed. 147 
Seroconversion in the Setting of PrEP
Diagnosing HIV infection in individuals taking
Future Directions
New treatments continue to be developed, most notably longacting formulations of antiretrovirals for treatment and prevention. Injectable rilpivirine combined with cabotegravir was successful in phase 2 studies 148 and is being evaluated in phase 3 clinical trials (NCT03299049). Also in development are implantable sustainedrelease platforms, nanoparticles, viral vector delivery, monoclonal antibodies, and other long-acting oral agents. 1 Injectable and other long-acting preparations for PrEP, such as injectable cabotegravir 149 and the dapivirine vaginal ring, are in clinical trials (NCT01617096). Open-label trials of the dapivirine vaginal ring demonstrated higher uptake and adherence than in the blinded trials, as well as HIV-1 incidence that was half the expected rate.
150,151
Broadly neutralizing antibodies (bNAbs) targeting conserved antigenic sites on the HIV-1 envelope trimer are being evaluated for therapy and prevention. [152] [153] [154] Newer approaches to increase the potency, breadth, 155 and half-life 156,157 of bNAbs, evaluate different methods of bNAb administration, 158 and assess the efficacy of combinations of bNAbs are being investigated. 159, 160 HIV cure efforts focus on inducing HIV expression from latently infected cells, augmenting the immune system to clear infected cells (eg, with therapeutic vaccines, checkpoint inhibitors, chimeric antigen receptor T cells), and using gene therapy to modify host CD4 cells to make them resistant to HIV. Using ART with a toll-like receptor 7 agonist (an innate immune stimulant) plus a bNAb during acute infection in monkeys suppressed viral rebound after stopping ART in a substantial number of animals. 161 These interventions are moving forward in clinical trials.
Clinicians who care for patients with HIV have a major role in advocating for programs and their patients at the local, national, and international levels. Advocacy should go beyond access to ART and include access to mental health and substance abuse services as well as efforts to end policies such as HIV criminalization that impede the ability to provide evidence-based care and prevention services.
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Evidence considered for updating the recommendations was limited to data published in the scientific literature, presented at major peer-reviewed scientific conferences, or released as safety reports by regulatory agencies or data safety and monitoring boards, since the last update in 2016 through February 2018. 2 Monthly literature searches are conducted by a systematic review methodologist at the University of California San Francisco. Each monthly publication list is reviewed by a panel member (Paul A. Volberding, MD) for relevance. Approximately 237 citations were ultimately identified from a list of more than 4490 over the 20 months. Relevant abstracts publically presented at recent scientific conferences were identified by panel members. Manufacturers of antiretroviral drugs were asked to submit lists of relevant publications or abstracts meeting the established criteria. All reference lists, published papers, abstracts, and other relevant reports were organized and stored on a web-based, shared, electronic drive to which all panel members have ongoing access.
These recommendations focus on HIV-1-infected adults in international, developed-world settings where antiretroviral drugs are generally available (approved by regulatory bodies or available by expanded access) or in late-stage development (new drug application filed). Recommendations were made by full-panel consensus and rated according to the strength of the recommendation and the quality of the supporting evidence (Manuscript Table 1 ). For areas in which recommendations have not changed substantially or no or few new data are available, the reader is referred to the previous report. 
II. Detailed Summary a. Background
The medical management of HIV changes rapidly, owing to the continued rapid advances in pathogenic and clinical knowledge leading to necessary changes in patient care, as well as ongoing availability of new drugs, formulations, and laboratory testing to optimally manage HIV infection. In 1995, on recognizing the rapidly changing knowledge base, the complexity of HIV management and expertise needed to provide quality care, and the lack of current plans to update any existing HIV guidelines, the need to disseminate reliable evidence-based guidance for clinicians involved in HIV management was clear. The IAS-USA International Antiretroviral Recommendations Panel was established in 1995 by the IAS-USA to develop this needed guidance for physicians and other clinicians actively involved in HIV care.
b. The IAS-USA and Its Role in the Recommendations
The IAS-USA is a 501(c)(3) not-for-profit, mission-based, nonmembership, educational organization that was established in 1992. The mission of the IAS-USA is to improve the treatment, care, and quality of life for people with HIV, hepatitis C virus (HCV), or other viral infections through highquality, relevant, balanced, and needs-oriented education and information for practitioners who are actively involved in medical care. The IAS-USA delivers annual continuing medical education (CME) programs on HIV and HCV that include live courses; live intensive, interactive workshops; live webinars; online interactive activities in the series Cases on the Web (COW); and the peer-reviewed, indexed journal Topics in Antiviral Medicine.™ In addition, IAS-USA manages and serves as the CME sponsor for the annual HRSA-supported Clinical Conference for Ryan White HIV/AIDS Program Practitioners, and for the annual Conference on Retroviruses and Opportunistic Infections (CROI), a research conference.
The IAS-USA is accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME) to provide CME for physicians.
IAS-USA has sponsored the development of evidence-based recommendations for viral load monitoring, antiretroviral therapy, HIV drug resistance testing, cytomegalovirus (CMV) infection, and the metabolic complications of antiretroviral therapy, all of which are published in the medical literature. 1, [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] In addition to the published recommendations, the IAS-USA served as the collaborating partner for the American Association for the Study of Liver Diseases (AASLD)/Infection Diseases Society of America (IDSA)/IAS-USA HCV Guidance (www.HCVguidelines.org) from its inception until January 2016.
The volunteer members of the IAS-USA Board of Directors (eBox 1) oversee the development of the information and educational programs and are not compensated for their roles in oversight and governance of the organization.
IAS-USA funding comes from a variety of sources. Largest single source of revenue is conference and CME participant registration fees. Other funding sources include grants from the pharmaceutical/diagnostics (commercial) industries, grants and subcontracts from government agencies, private donations, and gifts-in-kind from local community businesses and individuals. The commercial support that IAS-USA accepts is only for selected activities. Two large national CME efforts (one on HIV and another on HCV) invite funding in the form of educational grants from industry. Per IAS-USA policy, any effort that uses commercial grants must receive grants from several companies with competing products. Funds are pooled and distributed to activities within the effort at the sole discretion of the IAS-USA. Funders have no input into any activity, including its content, development, or selection of topics or speaker(s). Funders are listed in each activity as applicable.
The development of the Antiretroviral Therapy Recommendations is supported and funded by the IAS-USA. The IAS-USA determined the need for updated recommendations; selected panel members based on expertise in research and care to represent developed-world settings affected by HIV disease; determined the most appropriate way in which to dissemble the information (eg, publication in a medical journal rather than publication in the IAS-USA journal, web publication, etc); and provided administrative oversight and financial support.
The Panel itself is responsible for proposing the design and conduct of the work; collection, management, analysis, and interpretation of the data; and preparation, review, and approval of the manuscript. IAS-USA provided staff support for administrative management, oversight of literature searches and editorial and production assistance. At least one member of the Board serves in each panel to ensure continuing with the IAS-USA mission.
c. Identifying and Screening Panel Members
The panel was initially appointed in 1995, and members have rotated periodically since then. In evaluating potential participants for the Panel, the IAS-USA Board considered individuals who 1) are recognized as authorities in HIV treatment research and clinical care, 2) have appointments in major medical teaching or research institutions, 3) have a demonstrated ability to review and evaluate evidence in an effort to provide useful recommendations in the field, 4) meet the IAS-USA COI and financial relationship criteria for participation (see below and www.iasusa.org), and 5) have the ability to work in a collaborative consensus process. In addition, the Board emphasized the need for an international, developed world perspective.
Like the IAS-USA Board of Directors, participants in IAS-USA panels are volunteers and receive no financial compensation for their panel participation. In joining the Panel, members agree to commit substantial time to the effort necessary for evidence review and for participation in the consensus process.
d. COI Management
It is the policy of IAS-USA to ensure balance, independence, objectivity, and scientific rigor in all its activities. All parties with control over the content of IAS-USA activities are required to disclose to the organization and activity audience any financial interest or other relationship with the manufacturer(s) of any commercial product(s) or provider(s) of commercial services with interests discussed in the activity (eg, presentation, article, etc) within at least the past 12 months. Financial interests or other relationships can include receipt of grants or research support, status as employee or consultant, stock or options holder, paid lecturer, paid lecturer, writer, or author, or member of speakers bureau, of the party or of his or her spouse or partner. The ACCME defines a financial interest as an interest of any dollar amount. Part of the IAS-USA policies to ensure the integrity of its activities is the policy to separate commercial promotion from core IAS-USA educational and informational activities. Individuals who conduct marketing or promotional activities for commercial firms may not contribute to core IAS-USA programs. A marketing or promotional activity includes any activity in which the commercial entity controls key elements, such as speaker or topic selection, that could be used to serve the entity's commercial interests (eg, speakers bureaus, advertorials, etc). Individuals may not participate in most IAS-USA programs for 12 months after functioning in a promotional or marketing effort for a commercial firm. A notable exception to the separation policy is the annual Conference on Retroviruses and Opportunistic Infections (CROI) which allows research and symposia presentations by individuals with some of such relationships (including employment) because of its large focus on the presentations on original research, if their research or work passes rigorous peer review). Panel members who meet general criteria and are appointed, agree not to participate in any promotional activity on behalf of a pharmaceutical or medical device company (eg, serve on a speaker bureau, as a paid lecturer, or a similar contribution) while a member of the panel. Any conforming financial relationships with commercial entities that still may represent a real or potential COIs, will be resolved so that they do not influence the content of the recommendations. Prior to selection of the section teams and leaders, panel members declared their financial relationships with commercial concerns, discussed potential COIs, and recused themselves from serving as section leaders or team members accordingly.
III. The IAS-USA Antiretroviral Recommendations Panel
The members of the IAS-USA Antiretroviral Recommendations Panel are listed in eBox 2. The Panel convened in person in October 2017 to April 2018, and regularly by conference call. The chair oversees the discussions of the process and evidence review and manuscript development, and guides the group to consensus. Section leaders and teams were appointed to evaluate evidence and summarize panel discussions for each section.
IV. Rating the Recommendations
The Panel is divided by topic into working sections, each with a section leader. These sections are responsible for reviewing and screening evidence, developing preliminary recommendations, and presenting these to the full Panel for discussion, identification of further evidence, and consensus.
The selected rating system (Manuscript Table 1 ) combines 2 ratings for each recommendation. One rates the strength of the recommendation (strong, moderate, or limited support) and the other rates the quality of the evidence (ranging from Ia, based on evidence from 1 or more randomized controlled clinical trial[s] published in the peer-reviewed literature, to III, based on the Panel's analysis of the accumulated available evidence).
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V. Content of the Recommendations
The Panel agreed on the purpose, audience, and scope of these recommendations and on 8 main content sections (and subsections). Panel members were assigned to content sections based on their expertise and section leaders were appointed (eBox 3). The Panel Chair participates in all sections and reviews the entire manuscript, and Paul A. Volberding, MD, reviewed literature search results and identified relevant publications, and also reviewed the entire manuscript.
From October 2017 to June 2018, sections met in person and by conference call and e-mail exchange. Initial discussions were used to develop detailed Section outlines, and assign participants to draft subsections. The full Panel reviewed sections and the final manuscript.
VI. Evidence Collection and Literature Searches
Panel members were selected based on their active work in the field of HIV research and care, and detailed knowledge of available evidence (published and presented at major scientific conferences).
Literature searches in PubMed and Embase were conducted and designed by an expert in systematic reviews, Hacsi Horvath and one of the panel members, Paul Volberding (eTable 1). The initial literature search provided data available since the 2016 publication of the recommendations through February 2018; approximately 237 references were ultimately identified. Relevant abstracts publically presented at recent scientific conferences were identified by panel members. All manufacturers of FDAapproved antiretroviral drugs were asked to submit lists of publications or abstracts meeting the established criteria (eTable 2). Drug manufacturers were instructed to provide references and electronic copies of the published or presented papers or abstracts only and not to comment on the design, methods, results or implications of any of the work. All reference lists, published papers, abstracts, and other relevant reports were organized and stored on a web-based, shared, electronic drive to which all panel members have ongoing access. • Any information about newly recognized toxicities and complications associated with your product(s) would be helpful.
Janssen Therapeutics • Presented at national or international conferences or has been published in the peerreviewed literature • Data should be from prospective clinical trials (ie, properly randomized controlled trials), cohort studies, and ancillary trials (pharmacologic and drug interaction studies) • Any information about newly recognized toxicities and complications associated with your product(s) would be helpful. ViiV Healthcare • Presented at national or international conferences or has been published in the peerreviewed literature • Data should be from prospective clinical trials (ie, properly randomized controlled trials), cohort studies, and ancillary trials (pharmacologic and drug interaction studies) • Any information about newly recognized toxicities and complications associated with your product(s) would be helpful.
